Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.
Journal: Leukemia & lymphoma
Published: July 29, 2026
Graft-versus-host disease prophylaxis with abatacept plus intermediate dose cyclophosphamide for GVHD prophylaxis after peripheral blood stem transplantation: a single institution study.
Journal: Bone marrow transplantation
Published: May 21, 2026
Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.
Journal: Haematologica
Published: January 13, 2026
Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.
Journal: Haematologica
Published: December 23, 2024
Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.
Journal: JMIR cancer
Published: October 28, 2024
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification.
Journal: Blood cancer journal
Published: October 17, 2024
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 19, 2023
A Co-Management Model for Myeloid Malignancies That Evolved during the COVID-19 Pandemic.
Journal: Acta haematologica
Published: May 06, 2022
Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave.
Journal: Cancer cell
Published: February 27, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026